Author

I. Petrini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Assay:fluorescence / live-cell microscopy· 1 Approach:microscopy & imaging analysis· 1 Approach:statistical model· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A. Diaspro· 1 shared A. Magi· 1 shared A. Mingrino· 1 shared B. Storti· 1 shared F. Martignano· 1 shared I. Nepita· 1 shared M. Castello· 1 shared M. Del Re· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiophysics

A. Diaspro

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Nanoscale engagement and clusterization of Programmed death ligand 1 (PD-L1) in the membrane lipid rafts of Non-Small Cell Lung Cancer cells

M. Ruglioni, S. Civita, T. Salvadori, S. Cristiani, V. Carnicelli, S. Barachini, I. Petrini, I. Nepita, M. Castello, A. Diaspro, P. Bianchini, B. Storti, R. Bizzarri, S. Fogli, R. Danesi

This study uses super-resolution microscopy to show PD-L1 clusters in lipid rafts of NSCLC cells, suggesting new immuno-oncology targets.

bioRxiv · Aug 9, 2022 · PreprintBiophysics

Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients

F. Martignano, S. Crucitta, A. Mingrino, R. Semeraro, M. Del Re, I. Petrini, A. Magi, S. G. Conticello

This study uses Nanopore sequencing on cell-free DNA from lung cancer patients to analyze copy number variations, showing it is a viable alternative to Illumina sequencing for rapid and cost-effective tumor DNA profiling.

Molecular Cancer · Dec 1, 2021Peer-reviewedCancer Biology